Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I could care less if it does I'm long anyways and I add Dips. But you have an agenda because you add no DD and only post the sky is falling on all the boards you post on. We only have like 10 active posters here and we all know what you own. No real volume yet....so not sure who your preaching to.
We post DD and company info, we disect the financials and advancements with the company. It is not cheerleading IMO. No one is standing on a soapbox shouting BUY BUY BUY. Read the DD here, do your own DD and make an informed decision.
Wow... you full of yourself aren't you? So what, you just go from board to board bashing stocks ?(link below) This board is too strong with investors who know their DD and hold major positions. So your truly wasting your time here with STEV's current activity and volume for a quick flip.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108497490
Welcome.. 2015 is going to be very impressive here. Great board here. Excellent DD. Any questions dont hesitate to let us know.
New website coming!
www.steviacorp.com
He never was a Dr. At least medical
Just returning a favor minster. Doesnt it suck when people troll?
BILLIONS of shares. Only matter of time. You know it.
Oh stop. This was already diluted into a POS. Not set up for shareholder success anymore. Its done
and what has that been doing for you ...lol.
Thank you, thank you, thank you = Red, Red, Red
Billions Outstanding = shareholder ATM . Nothing with billions outstanding will survive in this sector. Period.
Cut your losses and find a better SS.
There's no news cause shareholders are being used as an ATM. Cmon, what OTC doesn't release any news of substance in 4 months?
Exactly
This one is done. That's too bad too, they had a great product....lol
Nice bid support above .08. almost 500k/$40k.
*edit* NITE has 200k+ on the bid at .08. Hidden now by higher bid orders.
Bid support coming in. Time to move her back to the .20's
NEWS! Getting the team assembled for FDA approval?
CAESAREA, Israel, Nov. 24, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that Dr. Peter Kash and Ms. Hila Karah have been appointed to serve on the company's Board of Directors.
Dr. Kash and Ms. Karah bring significant experience in commercialization, finance and corporate governance of life science companies to LabStyle's board as the company increases its market penetration of the Dario™ blood glucose monitoring and diabetes management system. LabStyle is currently focused on executing its promising strategy for growth by penetrating and expanding into new markets in Europe, North America, Latin American and the Asia Pacific region. Based on their experiences, LabStyle expects Dr. Kash and Ms. Karah to bring significant value to the company's current and future growth plans. Ms. Karah is expected to serve on the Compensation and Nominating Committees of the board.
Dr. Kash and Ms. Karah are the designated appointees of Dicilyon Consulting and Investment Ltd., the lead investor in LabStyle's September 2014 private placement. Dicilyon, held by Mr. David Edery, holds the right to appoint 3 members of LabStyle's board. To accommodate these appointments, Dr. Oren Fuerst and Dr. Steven Kaplan have resigned from LabStyle's board. As Dr. Fuerst served as Chairman of the Board, the board has appointed Erez Raphael, LabStyle's President, Chief Executive Officer and a director, to serve as the Acting Chairman of the Board.
Dr. Kash currently serves as Executive Chairman of iOS app developer Time Flash LLC. He has also since 2005 served as the President of investment bank RiverBank Capital Securities, a FINRA member firm. He has co-founded and led investments in more than a dozen successful biotechnology companies and served on numerous boards of directors, including Keryx Biopharmaceuticals, Velcera, Inc. and Intercept Pharmaceuticals. He is a distinguished author of several books on business and healthcare, a lecturer on entrepreneurship, and has served as an Adjunct Professor at the Wharton School of Business. Dr. Kash received his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. Mr. Kash also holds doctorate in education from Yeshiva University.
Ms. Karah is an independent business consultant and an investor in several high-tech, biotech and Internet companies. Ms. Karah serves as a director in several private and public companies including Intec Pharma since 2009 and Cyren Ltd. since 2008. She served as a partner and Chief Investment Officer of Eurotrust Ltd., a family office, and as a research analyst both at Perceptive Life Sciences Ltd. a New York based hedge fund, and at Oracle Partners Ltd., a Connecticut based hedge fund. Ms. Karah holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and studied at the University of California, Berkeley-University of California, San Francisco Joint Medical Program.
LabStyle believes that the changes to its board represent a further step to better positioning the company to fulfill its business prospects as it moves forward with the commercialization efforts for Dario™. LabStyle's board offers it's thanks to Dr. Oren Fuerst for his tremendous contribution to the company. Dr. Fuerst played a key role in envisioning the Dario™ technology and opportunity and to building LabStyle from the ground up, and the board wishes him much success in his future endeavors. The board also thanks Dr. Steven Kaplan for his contributions to LabStyle.
New subsidiary...even more revenue going forward.. Lets get some buying above .09 today.
Having a 70 degree day here in the NE in late NOV is like walking into your favorite store and them hand you a 50% off coupon at the door.
Thrilled to enter in here below $14. Its going to be a cold one this year
Entered here. Thanks for your info last week.
Regardless.. there are no real walls here that a little volume wouldnt collapse. Until we get volume the smallest blocks seem like walls. Hopefully we get the launch of realhempstore before years end to keep investors thirst quenched until we get to our harvest fins. Hoping to hear some info on hemp harvest as well.
Ok pulled over.. same amount from S1 in april. Just stating they were sold and exercised.
Dont believe so its the same amount as earlier this year. Im driving so Ill look closer tonight.
We knew that though from calling the TA every week lol.
Not news really...
Prospectus to show shares diluted this summer were exercised in full it looks like.
Ok so your "long as long gets" so what exactly is getting worse standon? The fins are good. The SS is good. The convertible debt is now under control. So whats getting worse? The SHORT term pps isnt skyrocketing? You most definetly are not a long. Longs arent focused with short term pps and you are obsessed over it.
Since when do IRS rules not apply to an OTC company. Show me a link to that one. I will reach out to a buddy of mine who does IR and see if a SD credit exisits for a situation like this. I'll post if I get some info.
Thanks
thank you
I have to tend to think that STEV doesnt fit the criteria for a share depriciation credit. This stock has only traded over the share price of .12 for about 2 months this entire fiscal. A spike on news catalyst is what had this briefly trading higher. That doesnt seem like a monthly average you can calculate into a share depriciation. Technically this was only over .20 for a few weeks. So, with that said whats stopping any company shooting out a ridicilous PR to spike their PPS knowing it will sell off then filing for depriciation on that one time spike value. Where I see a SD would come in play is that you have an average PPS of 1 value for a fiscal year and significant dip off your normal average trading PPS. I'd be surprised if this even applies here.
Ok , I was just confused when you referenced Q1 in your post. Thoughts on the latest FINS? What you expected.. better?..worse?
Thanks BD
I think there is some confusion as to STEV's fiscal year and what quarter we are in. TM posted this yesterday and I believe he's correct. Or is he wrong with stating Q4 is STEV's big one?
Keep in mind STEV's fiscal year ends 3/31, and Q2 is the first quarter of the new fiscal year. So this will be the second quarter of STEV’s fiscal year:
Q1 2013 - $957,261
Q1 2014 - $2,217,026 (up $1.35M) (130% increase)
Q2 2013 – $547,858
Q2 2014 – (Should be out Friday)
Q3 2013 – $388,746
Q3 2014 –
Q4 2013 - $4,479,334
Q4 2014 -
2013 Fiscal (Ended 3/31/14) – $6,373,199
2014 Fiscal (Ends 3/31/15) - $2,217,026 (was $957,261 at this point in 2013)
-----------------------
Quick financial notes from the last quarter (Q1 2014):
Link: archive.fast-edgar.com//20140819/APK2H22CZ222TJZ2222N2ZZZQMOA4Y823262/
1. Total assets up over 20% to $5.48M, including over $3M in prepaid seeds and fertilizer.
2. Total current liabilities down over from $1.3M to $913K
3. Total liabilities down from $6.74M to $2.4M
4. Total equity up from -$2.35M to $3.09M
5. Revenue up from $957K to $2.2M
6. Gross margin up from -$144K to $480K
7. EPS up from -$.02 to .01
Takeaway: Assets up, current and total liabilities significantly down, equity significantly higher, revenues more than doubled. Gross margin shows the business model is making money. Revenue growth is VERY strong...AGAIN. Great quarter over quarter and year over year growth.
------------------------------------------
Quick Company Notes:
Already purchased all the seeds/fertilizer for Spring 2015 harvest
PG. 29 of 10q:
*The company acquired certain seeds and fertilizer in the amount of $3,136,630 in aggregate which was used for preparation of the fall planting for the spring harvest which will start from the second half of February, 2015 and last through April, 2015. In Q1 and Q2 2015 operating (farm) expenses will be significantly lower! This expense has already been paid for and $STEV still showed a positive gross margin and earnings per share!
----------------------
STEV's biggest quarter every year is their fiscal Q4 (Jan1 - March 31) because of the harvest. In 2014 over $4M in revs.
Thank you, a friend suggested looking into UGAZ this year. I just got around to it and trying to do some DD and understand how this trades.
Appriciate the info.
Warm up? LOL
Happy Birthday.. my Bday as well today.
Enjoy
Haha I thought that months ago. In time. I think we all know 2015 this shines. The OTC has taken a bath.. although loosely tied ...the MJ sector got destroyed and will most likely look to recover starting in Jan. I believe Ill be right here or at least I hope so.
Operating costs down again. Like stated our big quarter is Q4 for obvious reasons. I believe with realhemp revenues along with more aquaculture revenue deals that this company will start turning impressive profit growth in all quarters. But I am still very impressed with this balance sheet. Its night and day for what usually gets shoved down the throats of an OTC stock investor. Most companies are up to there eyeballs in debt and convertable notes. None of that toxic BS here. Now are probably not quite at the point that we trade on financials but by the time we do... we look to be heading in a very positive direction.
Anyone else notice we have formed another subsidiary SC Royal Andaman LLC?
Huge texas.. this is an excellent 10Q. Lots to digest but once over looks much better then expected.
That's why I'm here. Still cant understand how the market doesn't see how undervalued this is and how a P/E correction is inevitable. They will very soon though. Pumping out FINS like they are Q after Q will demand attention here. Good times ahead Knife...for sure.
This 10Q will not push it to .25 that's a PPS Increase of .17 or 200%. Need to be realistic here. Also the annual 10K you speak of is filed on July 15th.
Define "near". But yes it will IMO see .25 sometime early next year.
Nice job TM, excellent breakdown and analysis as always of the pending 10Q. I am also expecting an even more impressive balance sheet this quarter then we saw in Q1.
Yes 2015 will be very nice indeed.
Thanks Again